Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncology Pharma Inc ONPH

Oncology Pharma, Inc. is an oncology company. The Company is focused on licensing, developing, manufacturing and commercializing therapeutics. The Company’s research, development, and commercialization of therapeutic drugs and medical devices designed for the treatment of many types of cancers. The Company offers a portfolio, such as Nanosmart Pharmaceuticals Inc. (Nanosmart Pharmaceuticals). The Company’s NanoSmart platform technology is a human-derived, antinuclear antibody (ANA) that targets areas of necrosis present in solid tumors. Its anti-cancer drugs in combination with medications, for treating a variety of cancers, such as breast, ovarian, lung, bladder, Kaposi's sarcoma, lymphoma and acute lymphocytic leukemia is doxorubicin. Its portfolio also includes Connect2Med, Sybleu, Inc. and Regen.


GREY:ONPH - Post by User

Post by Carolpeters24on Jul 26, 2022 10:31am
869 Views
Post# 34850855

ValiRx and TheoremRx - VAL201 - US$61M plus royalties

ValiRx and TheoremRx - VAL201 - US$61M plus royalties Dr Ken Sorensen, Chairman of TheoremRx We are delighted out latest fundraising od $250m has brought in multiple financial institutions as we now move forward with our strategic plans.
Dr Ken Sorensen, Chairman of TheoremRx stated:
 "We have appreciated the work carried out so far, and we will now move forward with VAL201 as it is an important part of our pipeline of new projects."
First payments to ValiRx are expected on or before the end of July.
The proposed sub-licence of VAL201 to TheoremRx Inc. VAL201's primary indication is for prostate cancer, with potential further research & development in breast and ovarian cancer. 
The potential value of the deal would be in excess of US$61M plus royalties for the first cancer indication alone. Each oncology indication successfully developed to by TheoremRx will generate up to $37.5M of additional value to ValiRx. The proposed deal structure comprises payments on signature of the Licence Agreement plus fees and near-term milestones totalling US$2.2M before the end of 2023, milestones on further clinical and commercial development events, and royalties. The first payments are expected by the end of July 2022.
https://www.fidelity.co.uk/shares/stock-market-news/company-news/
Bullboard Posts
Next >>